nodes	percent_of_prediction	percent_of_DWPC	metapath
Perflutren—Connective tissue disorder—Vincristine—muscle cancer	0.00591	0.00591	CcSEcCtD
Perflutren—Erythema—Dactinomycin—muscle cancer	0.00586	0.00586	CcSEcCtD
Perflutren—Cardiac disorder—Vincristine—muscle cancer	0.00558	0.00558	CcSEcCtD
Perflutren—Ventricular extrasystoles—Doxorubicin—muscle cancer	0.00557	0.00557	CcSEcCtD
Perflutren—Angiopathy—Vincristine—muscle cancer	0.00545	0.00545	CcSEcCtD
Perflutren—Ill-defined disorder—Dactinomycin—muscle cancer	0.00543	0.00543	CcSEcCtD
Perflutren—Mediastinal disorder—Vincristine—muscle cancer	0.00542	0.00542	CcSEcCtD
Perflutren—Neuropathy peripheral—Etoposide—muscle cancer	0.00532	0.00532	CcSEcCtD
Perflutren—Coma—Methotrexate—muscle cancer	0.00531	0.00531	CcSEcCtD
Perflutren—Malaise—Dactinomycin—muscle cancer	0.00528	0.00528	CcSEcCtD
Perflutren—Leukopenia—Dactinomycin—muscle cancer	0.00524	0.00524	CcSEcCtD
Perflutren—Neck pain—Doxorubicin—muscle cancer	0.00509	0.00509	CcSEcCtD
Perflutren—Musculoskeletal pain—Doxorubicin—muscle cancer	0.00509	0.00509	CcSEcCtD
Perflutren—Back pain—Vincristine—muscle cancer	0.00506	0.00506	CcSEcCtD
Perflutren—Ventricular tachycardia—Doxorubicin—muscle cancer	0.00503	0.00503	CcSEcCtD
Perflutren—Injection site reaction—Doxorubicin—muscle cancer	0.005	0.005	CcSEcCtD
Perflutren—Myalgia—Dactinomycin—muscle cancer	0.00498	0.00498	CcSEcCtD
Perflutren—Lymphadenopathy—Methotrexate—muscle cancer	0.00494	0.00494	CcSEcCtD
Perflutren—Discomfort—Dactinomycin—muscle cancer	0.00492	0.00492	CcSEcCtD
Perflutren—Influenza like illness—Doxorubicin—muscle cancer	0.00488	0.00488	CcSEcCtD
Perflutren—Hypoaesthesia—Etoposide—muscle cancer	0.00484	0.00484	CcSEcCtD
Perflutren—Agitation—Vincristine—muscle cancer	0.00481	0.00481	CcSEcCtD
Perflutren—Oedema—Dactinomycin—muscle cancer	0.00478	0.00478	CcSEcCtD
Perflutren—Vertigo—Vincristine—muscle cancer	0.0047	0.0047	CcSEcCtD
Perflutren—Leukopenia—Vincristine—muscle cancer	0.00468	0.00468	CcSEcCtD
Perflutren—Cramps of lower extremities—Doxorubicin—muscle cancer	0.00462	0.00462	CcSEcCtD
Perflutren—Coma—Doxorubicin—muscle cancer	0.00459	0.00459	CcSEcCtD
Perflutren—Eye disorder—Etoposide—muscle cancer	0.00455	0.00455	CcSEcCtD
Perflutren—Convulsion—Vincristine—muscle cancer	0.00453	0.00453	CcSEcCtD
Perflutren—Cardiac disorder—Etoposide—muscle cancer	0.00452	0.00452	CcSEcCtD
Perflutren—Flushing—Etoposide—muscle cancer	0.00452	0.00452	CcSEcCtD
Perflutren—Hypertension—Vincristine—muscle cancer	0.00452	0.00452	CcSEcCtD
Perflutren—Myalgia—Vincristine—muscle cancer	0.00445	0.00445	CcSEcCtD
Perflutren—Visual disturbance—Methotrexate—muscle cancer	0.00445	0.00445	CcSEcCtD
Perflutren—Angiopathy—Etoposide—muscle cancer	0.00442	0.00442	CcSEcCtD
Perflutren—Hypertonia—Doxorubicin—muscle cancer	0.00441	0.00441	CcSEcCtD
Perflutren—Immune system disorder—Etoposide—muscle cancer	0.0044	0.0044	CcSEcCtD
Perflutren—Mediastinal disorder—Etoposide—muscle cancer	0.00439	0.00439	CcSEcCtD
Perflutren—Abnormal vision—Doxorubicin—muscle cancer	0.00438	0.00438	CcSEcCtD
Perflutren—Chills—Etoposide—muscle cancer	0.00437	0.00437	CcSEcCtD
Perflutren—Anaphylactoid reaction—Methotrexate—muscle cancer	0.00435	0.00435	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00435	0.00435	CcSEcCtD
Perflutren—Lymphadenopathy—Doxorubicin—muscle cancer	0.00428	0.00428	CcSEcCtD
Perflutren—Oedema—Vincristine—muscle cancer	0.00427	0.00427	CcSEcCtD
Perflutren—Anaphylactic shock—Vincristine—muscle cancer	0.00427	0.00427	CcSEcCtD
Perflutren—Nervous system disorder—Vincristine—muscle cancer	0.00419	0.00419	CcSEcCtD
Perflutren—Dysgeusia—Etoposide—muscle cancer	0.00415	0.00415	CcSEcCtD
Perflutren—Hyperhidrosis—Vincristine—muscle cancer	0.00413	0.00413	CcSEcCtD
Perflutren—Fatigue—Dactinomycin—muscle cancer	0.00412	0.00412	CcSEcCtD
Perflutren—Back pain—Etoposide—muscle cancer	0.0041	0.0041	CcSEcCtD
Perflutren—Pain—Dactinomycin—muscle cancer	0.00409	0.00409	CcSEcCtD
Perflutren—Muscle spasms—Etoposide—muscle cancer	0.00407	0.00407	CcSEcCtD
Perflutren—Cardiac failure congestive—Doxorubicin—muscle cancer	0.00402	0.00402	CcSEcCtD
Perflutren—Hypotension—Vincristine—muscle cancer	0.00399	0.00399	CcSEcCtD
Perflutren—Feeling abnormal—Dactinomycin—muscle cancer	0.00394	0.00394	CcSEcCtD
Perflutren—Ill-defined disorder—Etoposide—muscle cancer	0.00393	0.00393	CcSEcCtD
Perflutren—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00391	0.00391	CcSEcCtD
Perflutren—Hot flush—Doxorubicin—muscle cancer	0.0039	0.0039	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00389	0.00389	CcSEcCtD
Perflutren—Menopausal symptoms—Doxorubicin—muscle cancer	0.00387	0.00387	CcSEcCtD
Perflutren—Paraesthesia—Vincristine—muscle cancer	0.00383	0.00383	CcSEcCtD
Perflutren—Malaise—Etoposide—muscle cancer	0.00382	0.00382	CcSEcCtD
Perflutren—Vertigo—Etoposide—muscle cancer	0.00381	0.00381	CcSEcCtD
Perflutren—Leukopenia—Etoposide—muscle cancer	0.00379	0.00379	CcSEcCtD
Perflutren—Body temperature increased—Dactinomycin—muscle cancer	0.00378	0.00378	CcSEcCtD
Perflutren—Abdominal pain—Dactinomycin—muscle cancer	0.00378	0.00378	CcSEcCtD
Perflutren—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.00377	0.00377	CcSEcCtD
Perflutren—Loss of consciousness—Etoposide—muscle cancer	0.00372	0.00372	CcSEcCtD
Perflutren—Cough—Etoposide—muscle cancer	0.0037	0.0037	CcSEcCtD
Perflutren—Gastrointestinal disorder—Vincristine—muscle cancer	0.00369	0.00369	CcSEcCtD
Perflutren—Fatigue—Vincristine—muscle cancer	0.00368	0.00368	CcSEcCtD
Perflutren—Convulsion—Etoposide—muscle cancer	0.00367	0.00367	CcSEcCtD
Perflutren—Hypertension—Etoposide—muscle cancer	0.00366	0.00366	CcSEcCtD
Perflutren—Pain—Vincristine—muscle cancer	0.00365	0.00365	CcSEcCtD
Perflutren—Chest pain—Etoposide—muscle cancer	0.00361	0.00361	CcSEcCtD
Perflutren—Eosinophilia—Methotrexate—muscle cancer	0.00361	0.00361	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00358	0.00358	CcSEcCtD
Perflutren—Discomfort—Etoposide—muscle cancer	0.00356	0.00356	CcSEcCtD
Perflutren—Face oedema—Doxorubicin—muscle cancer	0.00352	0.00352	CcSEcCtD
Perflutren—Hypersensitivity—Dactinomycin—muscle cancer	0.00352	0.00352	CcSEcCtD
Perflutren—Gastrointestinal pain—Vincristine—muscle cancer	0.00349	0.00349	CcSEcCtD
Perflutren—Cardiac arrest—Doxorubicin—muscle cancer	0.00347	0.00347	CcSEcCtD
Perflutren—Anaphylactic shock—Etoposide—muscle cancer	0.00346	0.00346	CcSEcCtD
Perflutren—Asthenia—Dactinomycin—muscle cancer	0.00343	0.00343	CcSEcCtD
Perflutren—Tachycardia—Etoposide—muscle cancer	0.00338	0.00338	CcSEcCtD
Perflutren—Body temperature increased—Vincristine—muscle cancer	0.00337	0.00337	CcSEcCtD
Perflutren—Abdominal pain—Vincristine—muscle cancer	0.00337	0.00337	CcSEcCtD
Perflutren—Skin disorder—Etoposide—muscle cancer	0.00336	0.00336	CcSEcCtD
Perflutren—Dry skin—Doxorubicin—muscle cancer	0.00335	0.00335	CcSEcCtD
Perflutren—Hyperhidrosis—Etoposide—muscle cancer	0.00334	0.00334	CcSEcCtD
Perflutren—Diarrhoea—Dactinomycin—muscle cancer	0.00327	0.00327	CcSEcCtD
Perflutren—Hypotension—Etoposide—muscle cancer	0.00323	0.00323	CcSEcCtD
Perflutren—Conjunctivitis—Methotrexate—muscle cancer	0.00316	0.00316	CcSEcCtD
Perflutren—Hypersensitivity—Vincristine—muscle cancer	0.00315	0.00315	CcSEcCtD
Perflutren—Eosinophilia—Doxorubicin—muscle cancer	0.00312	0.00312	CcSEcCtD
Perflutren—Paraesthesia—Etoposide—muscle cancer	0.00311	0.00311	CcSEcCtD
Perflutren—Dyspnoea—Etoposide—muscle cancer	0.00308	0.00308	CcSEcCtD
Perflutren—Asthenia—Vincristine—muscle cancer	0.00306	0.00306	CcSEcCtD
Perflutren—Vomiting—Dactinomycin—muscle cancer	0.00304	0.00304	CcSEcCtD
Perflutren—Rash—Dactinomycin—muscle cancer	0.00301	0.00301	CcSEcCtD
Perflutren—Gastrointestinal disorder—Etoposide—muscle cancer	0.00299	0.00299	CcSEcCtD
Perflutren—Fatigue—Etoposide—muscle cancer	0.00298	0.00298	CcSEcCtD
Perflutren—Pain—Etoposide—muscle cancer	0.00296	0.00296	CcSEcCtD
Perflutren—Haemoglobin—Methotrexate—muscle cancer	0.00293	0.00293	CcSEcCtD
Perflutren—Diarrhoea—Vincristine—muscle cancer	0.00292	0.00292	CcSEcCtD
Perflutren—Haemorrhage—Methotrexate—muscle cancer	0.00292	0.00292	CcSEcCtD
Perflutren—Pharyngitis—Methotrexate—muscle cancer	0.00289	0.00289	CcSEcCtD
Perflutren—Feeling abnormal—Etoposide—muscle cancer	0.00285	0.00285	CcSEcCtD
Perflutren—Nausea—Dactinomycin—muscle cancer	0.00284	0.00284	CcSEcCtD
Perflutren—Gastrointestinal pain—Etoposide—muscle cancer	0.00283	0.00283	CcSEcCtD
Perflutren—Dizziness—Vincristine—muscle cancer	0.00282	0.00282	CcSEcCtD
Perflutren—Visual impairment—Methotrexate—muscle cancer	0.00281	0.00281	CcSEcCtD
Perflutren—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00276	0.00276	CcSEcCtD
Perflutren—Urticaria—Etoposide—muscle cancer	0.00275	0.00275	CcSEcCtD
Perflutren—Abdominal pain—Etoposide—muscle cancer	0.00273	0.00273	CcSEcCtD
Perflutren—Body temperature increased—Etoposide—muscle cancer	0.00273	0.00273	CcSEcCtD
Perflutren—Conjunctivitis—Doxorubicin—muscle cancer	0.00273	0.00273	CcSEcCtD
Perflutren—Eye disorder—Methotrexate—muscle cancer	0.00272	0.00272	CcSEcCtD
Perflutren—Tinnitus—Methotrexate—muscle cancer	0.00272	0.00272	CcSEcCtD
Perflutren—Vomiting—Vincristine—muscle cancer	0.00271	0.00271	CcSEcCtD
Perflutren—Cardiac disorder—Methotrexate—muscle cancer	0.00271	0.00271	CcSEcCtD
Perflutren—Rash—Vincristine—muscle cancer	0.00269	0.00269	CcSEcCtD
Perflutren—Dermatitis—Vincristine—muscle cancer	0.00269	0.00269	CcSEcCtD
Perflutren—Headache—Vincristine—muscle cancer	0.00267	0.00267	CcSEcCtD
Perflutren—Angiopathy—Methotrexate—muscle cancer	0.00265	0.00265	CcSEcCtD
Perflutren—Immune system disorder—Methotrexate—muscle cancer	0.00263	0.00263	CcSEcCtD
Perflutren—Mediastinal disorder—Methotrexate—muscle cancer	0.00263	0.00263	CcSEcCtD
Perflutren—Chills—Methotrexate—muscle cancer	0.00262	0.00262	CcSEcCtD
Perflutren—Bradycardia—Doxorubicin—muscle cancer	0.00257	0.00257	CcSEcCtD
Perflutren—Hypersensitivity—Etoposide—muscle cancer	0.00255	0.00255	CcSEcCtD
Perflutren—Erythema—Methotrexate—muscle cancer	0.00254	0.00254	CcSEcCtD
Perflutren—Haemoglobin—Doxorubicin—muscle cancer	0.00254	0.00254	CcSEcCtD
Perflutren—Nausea—Vincristine—muscle cancer	0.00254	0.00254	CcSEcCtD
Perflutren—Rhinitis—Doxorubicin—muscle cancer	0.00253	0.00253	CcSEcCtD
Perflutren—Haemorrhage—Doxorubicin—muscle cancer	0.00252	0.00252	CcSEcCtD
Perflutren—Hypoaesthesia—Doxorubicin—muscle cancer	0.00251	0.00251	CcSEcCtD
Perflutren—Pharyngitis—Doxorubicin—muscle cancer	0.00251	0.00251	CcSEcCtD
Perflutren—Dysgeusia—Methotrexate—muscle cancer	0.00249	0.00249	CcSEcCtD
Perflutren—Asthenia—Etoposide—muscle cancer	0.00248	0.00248	CcSEcCtD
Perflutren—Connective tissue disorder—Doxorubicin—muscle cancer	0.00248	0.00248	CcSEcCtD
Perflutren—Back pain—Methotrexate—muscle cancer	0.00246	0.00246	CcSEcCtD
Perflutren—Pruritus—Etoposide—muscle cancer	0.00245	0.00245	CcSEcCtD
Perflutren—Visual impairment—Doxorubicin—muscle cancer	0.00243	0.00243	CcSEcCtD
Perflutren—Vision blurred—Methotrexate—muscle cancer	0.00239	0.00239	CcSEcCtD
Perflutren—Diarrhoea—Etoposide—muscle cancer	0.00237	0.00237	CcSEcCtD
Perflutren—Eye disorder—Doxorubicin—muscle cancer	0.00236	0.00236	CcSEcCtD
Perflutren—Ill-defined disorder—Methotrexate—muscle cancer	0.00236	0.00236	CcSEcCtD
Perflutren—Tinnitus—Doxorubicin—muscle cancer	0.00235	0.00235	CcSEcCtD
Perflutren—Flushing—Doxorubicin—muscle cancer	0.00234	0.00234	CcSEcCtD
Perflutren—Cardiac disorder—Doxorubicin—muscle cancer	0.00234	0.00234	CcSEcCtD
Perflutren—Angiopathy—Doxorubicin—muscle cancer	0.00229	0.00229	CcSEcCtD
Perflutren—Malaise—Methotrexate—muscle cancer	0.00229	0.00229	CcSEcCtD
Perflutren—Dizziness—Etoposide—muscle cancer	0.00229	0.00229	CcSEcCtD
Perflutren—Immune system disorder—Doxorubicin—muscle cancer	0.00228	0.00228	CcSEcCtD
Perflutren—Vertigo—Methotrexate—muscle cancer	0.00228	0.00228	CcSEcCtD
Perflutren—Mediastinal disorder—Doxorubicin—muscle cancer	0.00228	0.00228	CcSEcCtD
Perflutren—Leukopenia—Methotrexate—muscle cancer	0.00227	0.00227	CcSEcCtD
Perflutren—Chills—Doxorubicin—muscle cancer	0.00227	0.00227	CcSEcCtD
Perflutren—Arrhythmia—Doxorubicin—muscle cancer	0.00226	0.00226	CcSEcCtD
Perflutren—Cough—Methotrexate—muscle cancer	0.00221	0.00221	CcSEcCtD
Perflutren—Convulsion—Methotrexate—muscle cancer	0.0022	0.0022	CcSEcCtD
Perflutren—Vomiting—Etoposide—muscle cancer	0.0022	0.0022	CcSEcCtD
Perflutren—Erythema—Doxorubicin—muscle cancer	0.0022	0.0022	CcSEcCtD
Perflutren—Rash—Etoposide—muscle cancer	0.00218	0.00218	CcSEcCtD
Perflutren—Dermatitis—Etoposide—muscle cancer	0.00218	0.00218	CcSEcCtD
Perflutren—Headache—Etoposide—muscle cancer	0.00217	0.00217	CcSEcCtD
Perflutren—Arthralgia—Methotrexate—muscle cancer	0.00216	0.00216	CcSEcCtD
Perflutren—Myalgia—Methotrexate—muscle cancer	0.00216	0.00216	CcSEcCtD
Perflutren—Chest pain—Methotrexate—muscle cancer	0.00216	0.00216	CcSEcCtD
Perflutren—Dysgeusia—Doxorubicin—muscle cancer	0.00215	0.00215	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00215	0.00215	CcSEcCtD
Perflutren—Discomfort—Methotrexate—muscle cancer	0.00214	0.00214	CcSEcCtD
Perflutren—Back pain—Doxorubicin—muscle cancer	0.00213	0.00213	CcSEcCtD
Perflutren—Muscle spasms—Doxorubicin—muscle cancer	0.00211	0.00211	CcSEcCtD
Perflutren—Anaphylactic shock—Methotrexate—muscle cancer	0.00207	0.00207	CcSEcCtD
Perflutren—Vision blurred—Doxorubicin—muscle cancer	0.00207	0.00207	CcSEcCtD
Perflutren—Nausea—Etoposide—muscle cancer	0.00205	0.00205	CcSEcCtD
Perflutren—Ill-defined disorder—Doxorubicin—muscle cancer	0.00204	0.00204	CcSEcCtD
Perflutren—Nervous system disorder—Methotrexate—muscle cancer	0.00203	0.00203	CcSEcCtD
Perflutren—Agitation—Doxorubicin—muscle cancer	0.00202	0.00202	CcSEcCtD
Perflutren—Skin disorder—Methotrexate—muscle cancer	0.00201	0.00201	CcSEcCtD
Perflutren—Hyperhidrosis—Methotrexate—muscle cancer	0.002	0.002	CcSEcCtD
Perflutren—Malaise—Doxorubicin—muscle cancer	0.00198	0.00198	CcSEcCtD
Perflutren—Vertigo—Doxorubicin—muscle cancer	0.00197	0.00197	CcSEcCtD
Perflutren—Syncope—Doxorubicin—muscle cancer	0.00197	0.00197	CcSEcCtD
Perflutren—Leukopenia—Doxorubicin—muscle cancer	0.00197	0.00197	CcSEcCtD
Perflutren—Palpitations—Doxorubicin—muscle cancer	0.00194	0.00194	CcSEcCtD
Perflutren—Hypotension—Methotrexate—muscle cancer	0.00194	0.00194	CcSEcCtD
Perflutren—Loss of consciousness—Doxorubicin—muscle cancer	0.00193	0.00193	CcSEcCtD
Perflutren—Cough—Doxorubicin—muscle cancer	0.00192	0.00192	CcSEcCtD
Perflutren—Convulsion—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Perflutren—Hypertension—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00189	0.00189	CcSEcCtD
Perflutren—Arthralgia—Doxorubicin—muscle cancer	0.00187	0.00187	CcSEcCtD
Perflutren—Chest pain—Doxorubicin—muscle cancer	0.00187	0.00187	CcSEcCtD
Perflutren—Myalgia—Doxorubicin—muscle cancer	0.00187	0.00187	CcSEcCtD
Perflutren—Paraesthesia—Methotrexate—muscle cancer	0.00186	0.00186	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00186	0.00186	CcSEcCtD
Perflutren—Discomfort—Doxorubicin—muscle cancer	0.00185	0.00185	CcSEcCtD
Perflutren—Dyspnoea—Methotrexate—muscle cancer	0.00185	0.00185	CcSEcCtD
Perflutren—Dry mouth—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Perflutren—Dyspepsia—Methotrexate—muscle cancer	0.00182	0.00182	CcSEcCtD
Perflutren—Anaphylactic shock—Doxorubicin—muscle cancer	0.00179	0.00179	CcSEcCtD
Perflutren—Oedema—Doxorubicin—muscle cancer	0.00179	0.00179	CcSEcCtD
Perflutren—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00179	0.00179	CcSEcCtD
Perflutren—Fatigue—Methotrexate—muscle cancer	0.00179	0.00179	CcSEcCtD
Perflutren—Pain—Methotrexate—muscle cancer	0.00177	0.00177	CcSEcCtD
Perflutren—Shock—Doxorubicin—muscle cancer	0.00176	0.00176	CcSEcCtD
Perflutren—Nervous system disorder—Doxorubicin—muscle cancer	0.00176	0.00176	CcSEcCtD
Perflutren—Tachycardia—Doxorubicin—muscle cancer	0.00175	0.00175	CcSEcCtD
Perflutren—Skin disorder—Doxorubicin—muscle cancer	0.00174	0.00174	CcSEcCtD
Perflutren—Hyperhidrosis—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Perflutren—Feeling abnormal—Methotrexate—muscle cancer	0.00171	0.00171	CcSEcCtD
Perflutren—Gastrointestinal pain—Methotrexate—muscle cancer	0.00169	0.00169	CcSEcCtD
Perflutren—Hypotension—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Perflutren—Urticaria—Methotrexate—muscle cancer	0.00165	0.00165	CcSEcCtD
Perflutren—Body temperature increased—Methotrexate—muscle cancer	0.00164	0.00164	CcSEcCtD
Perflutren—Abdominal pain—Methotrexate—muscle cancer	0.00164	0.00164	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00163	0.00163	CcSEcCtD
Perflutren—Paraesthesia—Doxorubicin—muscle cancer	0.00161	0.00161	CcSEcCtD
Perflutren—Dyspnoea—Doxorubicin—muscle cancer	0.0016	0.0016	CcSEcCtD
Perflutren—Dyspepsia—Doxorubicin—muscle cancer	0.00158	0.00158	CcSEcCtD
Perflutren—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00155	0.00155	CcSEcCtD
Perflutren—Fatigue—Doxorubicin—muscle cancer	0.00155	0.00155	CcSEcCtD
Perflutren—Pain—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Perflutren—Hypersensitivity—Methotrexate—muscle cancer	0.00153	0.00153	CcSEcCtD
Perflutren—Asthenia—Methotrexate—muscle cancer	0.00149	0.00149	CcSEcCtD
Perflutren—Feeling abnormal—Doxorubicin—muscle cancer	0.00148	0.00148	CcSEcCtD
Perflutren—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Perflutren—Pruritus—Methotrexate—muscle cancer	0.00147	0.00147	CcSEcCtD
Perflutren—Urticaria—Doxorubicin—muscle cancer	0.00143	0.00143	CcSEcCtD
Perflutren—Abdominal pain—Doxorubicin—muscle cancer	0.00142	0.00142	CcSEcCtD
Perflutren—Body temperature increased—Doxorubicin—muscle cancer	0.00142	0.00142	CcSEcCtD
Perflutren—Diarrhoea—Methotrexate—muscle cancer	0.00142	0.00142	CcSEcCtD
Perflutren—Dizziness—Methotrexate—muscle cancer	0.00137	0.00137	CcSEcCtD
Perflutren—Hypersensitivity—Doxorubicin—muscle cancer	0.00132	0.00132	CcSEcCtD
Perflutren—Vomiting—Methotrexate—muscle cancer	0.00132	0.00132	CcSEcCtD
Perflutren—Rash—Methotrexate—muscle cancer	0.00131	0.00131	CcSEcCtD
Perflutren—Dermatitis—Methotrexate—muscle cancer	0.0013	0.0013	CcSEcCtD
Perflutren—Headache—Methotrexate—muscle cancer	0.0013	0.0013	CcSEcCtD
Perflutren—Asthenia—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Perflutren—Pruritus—Doxorubicin—muscle cancer	0.00127	0.00127	CcSEcCtD
Perflutren—Nausea—Methotrexate—muscle cancer	0.00123	0.00123	CcSEcCtD
Perflutren—Diarrhoea—Doxorubicin—muscle cancer	0.00123	0.00123	CcSEcCtD
Perflutren—Dizziness—Doxorubicin—muscle cancer	0.00119	0.00119	CcSEcCtD
Perflutren—Vomiting—Doxorubicin—muscle cancer	0.00114	0.00114	CcSEcCtD
Perflutren—Rash—Doxorubicin—muscle cancer	0.00113	0.00113	CcSEcCtD
Perflutren—Dermatitis—Doxorubicin—muscle cancer	0.00113	0.00113	CcSEcCtD
Perflutren—Headache—Doxorubicin—muscle cancer	0.00112	0.00112	CcSEcCtD
Perflutren—Nausea—Doxorubicin—muscle cancer	0.00107	0.00107	CcSEcCtD
